<DOC>
	<DOCNO>NCT00637039</DOCNO>
	<brief_summary>The main purpose study explore safety tolerability multiple ascending dos ( MAD ) AZD8931 patient advance solid malignancy</brief_summary>
	<brief_title>Study AZD8931 Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Cancer refractory standard therapy , standard therapy exist . Inclusion irrespective stage disease extent prior therapy . Histologically cytologically confirm solid , malignant tumour . Receipt follow treatment within 4 week prior study entry : chemotherapy ( within 6 week nitrosurea mitomycin C ) , radiotherapy , hormone therapy ( except androgendeprivation therapy patient prostate cancer ) , immunotherapy anticancer therapy . Unresolved toxicity ( stable toxicity ) previous anticancer therapy , except alopecia . History document cardiac failure , angina pectoris require antianginal medication , evidence transmural infarction ECG , poorly control hypertension ( systolic &gt; 180 mmHg diastolic &gt; 100 mmHg ) , significant valvular disease history high risk dysrrhythmia ( ventricular fibrillation ventricular tachycardia [ include ventricular triplet ] ) . Resting ECG measurable QTc interval &gt; 460 msec 2 timepoints within 24hour time period , history prolong QTc syndrome . The presence ocular disease condition active likely flare course study systemic disease/condition affect affect eye past may flare , treatment may adverse effect eye . Eye condition stable long standing , scar trauma , pinguecula , atrophic pterygium etc , consider reason exclude patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>Solid malignancy</keyword>
	<keyword>Neoplasms</keyword>
</DOC>